Accueil   Diary - News   All news Advanced BioDesign raises additional €9 million from Xerys Funds

Advanced BioDesign raises additional €9 million from Xerys Funds

 

 

Financing will enable company to initiate phase I clinical trial in acute
myeloid leukemia (AML)

 

Lyon, France, February 25, 2020 – Advanced BioDesign, dedicated to developing new therapies for overcoming tumor resistant cancers, announces today that it has raised an additional €9M ($9.8M) financing from Xerys Funds to pursue its clinical development.

 


This is the largest funding raised by Advanced BioDesign following successive fundraising operations since 2013, totalling close to €7.5M ($8.1M). Thanks to Xerys Funds, its longstanding investor, Advanced BioDesign has been able to undertake fundamental work on the mechanism of action for its lead compound ABD-3001 and consolidate knowledge on its anti-cancer properties.

 

 

Read the press release